Recent Press Releases

FDA Extends Market Exclusivity Six Months for BioMarin's Rare Disease Therapy KUVAN(R) (sapropterin dihydrochloride) Powder for Oral Solution and Tablets

FDA Extends Market Exclusivity Six Months for BioMarin's Rare Disease Therapy KUVAN(R) (sapropterin dihydrochloride) Powder for Oral Solution and Tablets New Convenient Form of KUVAN Now...

Bristol-Myers Squibb Submits New Drug Application to U.S. FDA for a Fixed-Dose Combination Tablet of Atazanavir Sulfate with Cobicistat for People Living with HIV-1

Bristol-Myers Squibb Submits New Drug Application to U.S. FDA for a Fixed-Dose Combination Tablet of Atazanavir Sulfate with Cobicistat for People Living with HIV-1 Atazanavir sulfate capsules are...

Novartis Vaccines appoints new Medical Affairs Director for North Europe

Novartis Vaccines appoints new Medical Affairs Director for North Europe 14 April 2014 – Novartis Vaccines is pleased to announce the appointment of Dr John Porter to the position of Medical...

Review of testosterone-containing medicines started

Review of testosterone-containing medicines started The European Medicines Agency has started a review of testosterone-containing medicines, mainly used in men who do not produce enough testosterone...

Pfizer's Ian Read Becomes PhRMA Board Chairman; Ken Frazier, George Scangos Assume New Posts

Pfizer's Ian Read Becomes PhRMA Board Chairman; Ken Frazier, George Scangos Assume New Posts Washington, D.C. (April 11, 2014) — Ian C. Read, chairman and CEO of Pfizer, Inc, was elected...

CVS Caremark Reports Traditional Drug Trend Increased by Just 0.8 Percent in 2013 While Overall Prescription Drug Trend is Up 3.8 Percent

CVS Caremark Reports Traditional Drug Trend Increased by Just 0.8 Percent in 2013 While Overall Prescription Drug Trend is Up 3.8 Percent Increase driven by rising drug prices, increasing utilization...

Vanda Pharmaceuticals Announces Availability of HETLIOZ™ (tasimelteon) for Non-24-Hour Sleep-Wake Disorder (Non-24)

Vanda Pharmaceuticals Announces Availability of HETLIOZ™ (tasimelteon) for Non-24-Hour Sleep-Wake Disorder (Non-24) Vanda launches HETLIOZSolutions™, a patient resource for information...

Cegedim Strategic Data: Worldwide Pharma Industry Sales Force Trends

Cegedim Strategic Data: Worldwide Pharma Industry Sales Force Trends Worldwide Pharma Industry Sales Force Trends China and emerging markets continue to add reps while use of digital advances but...

Lilly and T1D Exchange Announce Research Collaboration to Inform Development of New Initiatives to Advance Diabetes Care

Research Projects Will Use Real-World Evidence to Support People Living With Type 1 Diabetes

BOSTON and

Novartis appoints Jeff George as Division Head, Alcon as Kevin Buehler retires; Richard Francis named as new Division Head, Sandoz

Novartis appoints Jeff George as Division Head, Alcon as Kevin Buehler retires; Richard Francis named as new Division Head, Sandoz New leaders to continue to build global scale and innovation power...

Zogenix Update on Legal Action

Zogenix Update on Legal Action SAN DIEGO, April 8, 2014 /PRNewswire/ -- Today Zogenix presented its case in U.S. District Court in Boston requesting an immediate order staying the ban on the U.S....

Supplemental New Drug Application for IMBRUVICATM (ibrutinib) Submitted to the U.S. FDA

Supplemental New Drug Application for IMBRUVICATM (ibrutinib) Submitted to the U.S. FDA New submission based on positive Phase 3 data from the RESONATETM trial RARITAN, NJ, April 8, 2014 - Janssen...

NY Family Wins $9 Billion in Trial Over Cancer Linked to Diabetes Drug Actos

Takeda Pharmaceutical, Eli Lilly found liable for man's bladder cancer

LAFAYETTE, La., April 8, 2014

Lilly Responds to Verdict in Case of Terrence Allen, et al. v. Takeda

INDIANAPOLIS, April 8, 2014 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) issued the following state

FDA Approves Pradaxa® (dabigatran etexilate mesylate) for Treatment and Reduction in the Risk of Recurrence of Deep Venous Thrombosis and Pulmonary Embolism

FDA Approves Pradaxa® (dabigatran etexilate mesylate) for Treatment and Reduction in the Risk of Recurrence of Deep Venous Thrombosis and Pulmonary Embolism Three pivotal trials showed PRADAXA as...

Mallinckrodt Pharmaceuticals and Questcor Pharmaceuticals Enter into Definitive Merger Agreement under which Mallinckrodt will Acqure Questcor for Approximately $5.6 Billion, Creating a Diversified, High-Growth Specialty Pharmaceuticals Company

Mallinckrodt Pharmaceuticals and Questcor Pharmaceuticals Enter into Definitive Merger Agreement under which Mallinckrodt will Acqure Questcor for Approximately $5.6 Billion, Creating a Diversified,...

Sun Pharma to Acquire Ranbaxy in a US$ 4 Billion Landmark Transaction

Sun Pharma to Acquire Ranbaxy in a US$ 4 Billion Landmark Transaction To create world's 5th largest specialty generic pharma company No. 1 pharma company in India with leadership position in 13...

Diplomat to distribute Otezla® (apremilast), newly approved medication for psoriatic arthritis

Diplomat to distribute Otezla® (apremilast), newly approved medication for psoriatic arthritis FLINT, Mich. — Diplomat has announced that it is one of a select group of specialty pharmacies...

Lilly To Release Early-Stage Pipeline Data Targeting Key Cancer Pathways At AACR 2014

INDIANAPOLIS, April 6, 2014 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will present early-stage d